SFJ’s decision-making process aims at enhancing the probability of clinical and regulatory success and maximizing the future value of the asset. Decisions are made in collaboration with the sponsor. A few examples:
In 2012, SFJ began a partnership with Pfizer for the funding, design, and execution of a 452-patient global Phase 3 trial of dacomitinib (Vizimpro), a first line therapy for EGFR-mutated non small cell lung cancer. Upon the success of the trial, this once-daily oral medication received regulatory approvals globally between December 2018 and May 2019.
Within 9 months of the Co-Development Agreement closing, SFJ: